SCHEMBL2366410

SCHEMBL2366410

Cc1cnc(N2CCN(C(=O)c3ccc(N4CCOC4=O)cc3[N+](=O)[O-])CC2)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.45
BCR P11274 1/20 0.45
ALDH1A1 P00352 7/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 6/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
SLC6A9 P48067 1/20 0.41
SLC6A5 Q9Y345 1/20 0.41
LMNA P02545 2/20 0.39
CMA1 P23946 1/20 0.39
DCTPP1 Q9H773 1/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 4/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365724 0.89 LMNA (0.43) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2366011 0.88 LMNA (0.42) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2366227 0.87 TP53 (0.40) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2366019 0.86 HTT (0.43) ALDH1A1SMN1; SMN2MAPTKMT2ASLC6A9
SCHEMBL2366215 0.84 SLC6A9 (0.40) SMN1; SMN2MAPTSLC6A9SLC6A5LMNA
SCHEMBL2366954 0.84 CFTR (0.40) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2366279 0.83 KDM4E (0.39) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2366915 0.83 MEN1 (0.45) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2366295 0.83 TP53 (0.39) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2366221 0.83 MEN1 (0.44) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 ABL1 4111/4885BCR 4634/4885ALDH1A1 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.